Revivelife Clinic I Naturopath in Ottawa

CARDIOVASCULAR TESTING

Slide
CARDIO 1 BLOOD TEST

This is a traditional screen for the lipid panel which includes: Cholesterol, HDL-C, TG, LDL-C, CHOL/HDL-C Ratio. A calculation is made of your HDL% (HDL/Tchol) and TG/HDL ratios are also made which are more reflective of cholesterol profile risk. If you already have this lipid profile performed by your medical doctor simply bring it in to your visit for further analysis.
_____________________
May be recommended to screen heart health and to monitor the progress of therapies.

Slide
CARDIO 2 BLOOD TEST

As current research evolves there is new discoveries that assist us in the understanding of the mechanisms of cardiovascular damage. While high cholesterol has been the main focal point of CVD therapeutics for many years more reflective heart markers are now available. This cardio test evaluates more advanced markers and includes: Lipid Panel: Cholesterol, HDL-C, TG, LDL-C, CHOL/HDL-C Ratio and Advanced Markers: ApoA1, ApoB, Lp(a), A/B ratio, Homocysteine, hs- CRP, and fasting Insulin.
_____________________
May be recommended if you have a family history of heart disease, have been using traditional statins for cholesterol and want a more detailed review.

Slide
CARDIO 3
NMR BLOOD TEST

The NMR LipoProfile® test uses nuclear magnetic resonance (NMR) spectroscopy to directly measure the number of LDL particles and sizes, and HDL particles. The test also provides a standard cholesterol test and a calculation of one's risk of type 2 diabetes by assessing abnormalities in lipoprotein markers that are closely associated with insulin resistance (a precursor to type 2 diabetes). Includes the Lipid Panel: Cholesterol, HDL-C, TG, LDL-C, CHOL/HDL-C Ratio and Advanced Markers: NMRP (LDL particles, HDL particles) ApoA1, ApoB, Lp(a), A/B ratio, Homocysteine, hs- CRP, and fasting Insulin.
_____________________
Key for a comprehensive overview of your cardiovascular status, especially if you have a strong family history or are in perimenopause or andropause where hormones shift and your risk factors may increase.

Slide
DNA GENETIC
HEALTH & HORMONE TEST

This signature DNA Genetic Test Health & Hormones assess over 100 genes for Detoxification Pathways, Health Overall, Hormone Metabolism, Nutrition, Alcohol Tolerance, Vitamin & Minerals needs, Blood Sugar, Weight & Metabolism, Cardiovascular Health, Fitness (Exercise Performance & Impact) & Injury Risk.
_________________
Best suited to those who want the most comprehensive approach to DNA health.

Slide
ENDOPAT 2000

The EndoPAT 2000 is a non-invasive test assessing the health of your vessels through endothelial elasticity. The endothelium lines your blood vessels and produces nitric oxide which helps the blood vessels relax. Damage to the endothelial cells leads to endothelial dysfunction which may lead to vessel constriction, clot and dangerous plaque formation which are all risk factors for heart attack and stroke.
_____________________
Comprehensive evaluation can help to reverse cardiovascular disease and potentially do so without the use of prescription medications and their known side effects.

previous arrow
next arrow

faqs

Although the screening tests to date have been helpful providing basic screening information it does not tell the full story and research shows that lipid panel testing alone is not an accurate prediction of your risk of cardiovascular disease.

Clinical trials have shown that lowering LDL-C does reduce the risk for a cardiovascular event but only by 25% on average. In a nutshell, this means that standard drug therapy fails to address 75% of a person’s residual risk for cardiovascular disease. Angiograms (x-ray picture of the health of a vessel) even show that those who are using traditional drug therapies may have lower cholesterol by lipid panel tests but may not have healthy vessels.  It is actually advanced markers and the health of the endothelium (the lining of blood vessels) that give you a more reflective measure of cardiovascular risk.

Assessment of blood vessel health and inflammation is a key component in determining one’s true risk for heart health concerns. Advanced cardio tests are recommended which include additional blood work (apoA1, ApoB, Lp (a), Homocysteine, LP particle number & size, oxidized LDL, hs-CRP, fasting Insulin, HbA1C), and an in-office, non-invasive testing (EndoPAT 2000) which assesses the health of the endothelium.

We recommend a New Patient Visit for the most comprehensive approach to your health or a Pre-Lab Visit for a quick snapshot prior to lab testing and a Post-Lab consult to review your results.

Traditional methods of testing for cardiovascular disease have included a blood test for a lipid panel (cholesterol panel) and the use of various risk factors. The lipid panel is a measure of the amounts of fatty substances (lipids) in the blood and includes

TC (total cholesterol)
LDL-C (low-density lipoprotein cholesterol)
HDL-C (high-density lipoprotein cholesterol)
TG (triglycerides)

The focus most often for heart health has been LDL-C and HDL-C which are two key types of cholesterol:

LDL-C: classically defined as “bad cholesterol”. However, there are two key types of LDL-C which include small & dense LDL-C which are the true dangerous types of LDL-C that can penetrate vessel walls creating inflammation and damage and the large & fluffy LDL-C which are less of a risk to heart health.  Traditional lab lipid panel testing does not differentiate these types of LDL-C.
HDL-C: classically defined as “good cholesterol” which helps remove LDL-C from your blood vessels. It carries the “bad cholesterol” to the liver to be removed from the body.

  • ApoA1: Structural and functional component of lipoprotein particles that serve as transporters of cholesterol.  Apo A1 is the protein component of HDL-C and its concentration is inversely related to the risk of CVD.
  • ApoB: Structural and functional component of lipoprotein particles that serve as transporters of cholesterol. ApoB is the primary protein component of the LDL and VLDL. One molecule of Apo B is associated with each LDL or VLDL molecule, making Apo B a good indicator of CVD risk. It has been suggested that Apo B is a more reliable indicator of CVD than LDL-C since the measurement of Apo B is a direct measurement rather than a calculated measurement. In addition, the Apo B assay is not affected by hypertriglyceridemia, as is the case with the calculated LDL-C.
  • A/B ratio: The apo B/apo A-I ratio reflects the cholesterol transport and has been shown to be strongly related to the risk of Myocardial infarction, stroke, and other Cardiovascular manifestations.
  • Lp (a):  A marker for genetically-determined factors
  • Homocysteine: A marker for nutritional deficiencies that increase cardiovascular risk.
  • CRP-hs: A marker for inflammation & infection
  • Insulin (fasting): Elevated levels increase the risk of cardiovascular disease NMR LipoProfile®: Research shows that it is the cholesterol particle sizes and blood sugar that determine the relative risk for cardiovascular disease. 

Heart Disease in Blood Vessels (Atherosclerotic Disease) Signs & Symptoms:

Cardiovascular disease symptoms may be different for men and women. For instance, men are more likely to have chest pain; while women are more likely to have chest discomfort, shortness of breath, nausea, and extreme fatigue.

Symptoms can include:

  • Chest pain, chest tightness, chest pressure and chest discomfort (angina)
  • Shortness of breath
  • Pain, numbness, weakness or coldness in your legs or arms
  • Pain in the neck, jaw, throat, upper abdomen or back

Abnormal Heartbeats (Heart Arrhythmias) Signs & Symptoms:

  • Fluttering in your chest
  • Racing heartbeat (tachycardia)
  • Slow heartbeat (bradycardia)
  • Chest pain or discomfort
  • Shortness of breath
  • Lightheadedness
  • Dizziness
  • Fainting (syncope)

Heart Defect Signs & Symptoms:

Infants – Congenital:

  • Pale gray or blue skin color (cyanosis)
  • Swelling in the legs, abdomen or areas around the eyes
  • In an infant, shortness of breath during feedings, leading to poor weight gain

Adults:

  • Easily getting short of breath during exercise or activity
  • Easily tiring during exercise or activity
  • Swelling in the hands, ankles or feet

Weak Heart Muscle (dilated cardiomyopathy) Signs & Symptoms:

  • Breathlessness with exertion or at rest
  • Swelling of the legs, ankles and feet
  • Fatigue
  • Irregular heartbeats that feel rapid, pounding or fluttering
  • Dizziness, lightheadedness, and fainting

Heart Infections (endocarditis) Signs & Symptoms:

Endocarditis is an infection that affects the inner membrane that separates the chambers and valves of the heart (endocardium). Heart infection symptoms can include:

  • Fever
  • Shortness of breath
  • Weakness or fatigue
  • Swelling in your legs or abdomen
  • Changes in your heart rhythm
  • Dry or persistent cough
  • Skin rashes or unusual spots

Valvular Heart Disease Signs & Symptoms:

The heart has four valves — the aortic, mitral, pulmonary, and tricuspid valves — that open and close to direct blood flow through your heart. Valves may be damaged by a variety of conditions leading to narrowing (stenosis), leaking (regurgitation or insufficiency) or improper closing (prolapse).

Depending on which valve isn’t working properly, valvular heart disease symptoms generally include:

  • Fatigue
  • Shortness of breath
  • Irregular heartbeat
  • Swollen feet or ankles
  • Chest pain
  • Fainting (syncope)

When to See a Doctor Seek emergency medical care if you have these heart disease symptoms:

  • Chest pain
  • Shortness of breath
  • Fainting

Information courtesy of Mayo Clinic, Retrieved Feb 29, 2020.

The principal risks of developing cardiovascular disease include:

Age
ApoE Genetic Variant
Autoimmune Inflammatory Diseases (rheumatoid arthritis and systemic lupus erythematosus)
Blood Sugar Imbalance (insulin resistance, leptin resistance, diabetes)
Chronic Inflammation
Elevated Blood Lipids
Elevated C-Reactive Protein
Elevated Fibrinogen
Elevated Homocysteine
Elevated Lipoprotein (a)
Elevated Resistin
Elevated Serum Amyloid A (SAA)
Elevated Tumor Necrosis Factor-alpha (TNF-α)
Excess Alcohol
Genetic Link
High Blood Pressure
Hormone Imbalance
Hormone Imbalance or Aging Hormones (testosterone, estrogen)
Infectious Agents
Low Nutrients (EPA/DHA, D, K)
Microbiome Imbalance
Obesity
Periodontitis (Gum Disease)
Poor Lifestyle – Diet, Lack of Sleep, Stress, Smoking
Reduced Nitric Oxide

Your Naturopath or Nurse Practitioner will help assess which test is right for you, including an analysis of the most cost-efficient path of testing. We recommend a New Patient Visit with one of our Naturopathic Doctors for the most comprehensive approach to your health or a Pre-Lab Visit for a quick snapshot prior to lab testing as there are many tests available.  Lab testing alone is a one-dimensional picture of your health. The expertise of a health professional is required to create a three-dimensional picture for proper selection, and interpretation of lab testing. To complete your care we recommend booking your Post-Lab consult 2 weeks after testing to review your results and receive your tailored health plan.

Most of the advanced cardiovascular testing is not ordered by your General Practitioner under OHIP-based services on routine screening tests. Our goal is to assess your health by evaluating high-risk factors including genetics and then work in prevention.

+Are these cardiovascular tests covered under insurance plans?

Third-party insurance companies may cover all or a portion of your consultations. Most of the other integrative testing is not currently covered by private insurance companies. Please check with your individual provider for details and how to submit claims.

Your Revivelife clinician will review all findings and create a tailored plan to you based on what are the root causes of your cardiovascular imbalances. The use of tailored meal plans, nutrients, antioxidants, vitamins, minerals (oral or IV), herbs, probiotics, prebiotics, stress management and or acupuncture that promote healing are often advised. One strategy may include targeted B vitamins. In trial involving 81 people with mild-to-moderately high blood pressure who were not on blood pressure medication, a combination of L-arginine (2.4 grams) and vitamin B6 (3 mg), folic acid (0.4 mg), and vitamin B12 (2 mcg) improved vascular function (including blood pressure, endothelial health, and homocysteine levels) compared with placebo. 100

We recommend a New Patient Visit for the most comprehensive approach to your health or a Pre-Lab Visit for a quick snapshot before lab testing and a Post-Lab consult to review your results and receive your tailored health plan.

  1. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. The Canadian journal of cardiology. 2015;31(2):177-183.
  2. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN Journal of parenteral and enteral nutrition. 2008;32(6):638-644.
  3. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag. 2006;2(2):145-152.
  4. Wu SH, Liu Z, Ho SC. Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies. European journal of epidemiology. 2010;25(6):375-384.
  5. Saita E, Kondo K, Momiyama Y. Anti-Inflammatory Diet for Atherosclerosis and Coronary Artery Disease: Antioxidant Foods. Clinical Medicine Insights Cardiology. 2015;8(Suppl 3):61-65.
  6. Al-Mamari* A. Atherosclerosis and Physical Activity. Oman medical journal. 2009;24.
  7. Paffenbarger RS, Jr., Hyde RT, Wing AL, Hsieh CC. Physical activity, all-cause mortality, and longevity of college alumni. The New England journal of medicine. 1986;314(10):605-613.
  8. Oldridge N, Gottlieb M, Guyatt G, Jones N, Streiner D, Feeny D. Predictors of health-related quality of life with cardiac rehabilitation after acute myocardial infarction. J Cardiopulm Rehabil. 1998;18(2):95-103.
  9. Tell GS, Polak JF, Ward BJ, Kittner SJ, Savage PJ, Robbins J. Relation of smoking with carotid artery wall thickness and stenosis in older adults. The Cardiovascular Health Study. The Cardiovascular Health Study (CHS) Collaborative Research Group. Circulation. 1994;90(6):2905-2908.
  10. Head T, Daunert S, Goldschmidt-Clermont PJ. The Aging Risk and Atherosclerosis: A Fresh Look at Arterial Homeostasis. Frontiers in genetics. 2017;8:216-216.
  11. Pandey AK, Blaha MJ, Sharma K, et al. Family history of coronary heart disease and the incidence and progression of coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2014;232(2):369-376.
  12. Leiva E, Wehinger S, Guzman L, Orrego R. Role of Oxidized LDL in Atherosclerosis. In: Kumar SA, ed. Hypercholesterolemia. InTechOpen; 2015.
  13. Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol. 2011;22(4):254-261.
  14. Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arteriosclerosis, thrombosis, and vascular biology. 2012;32(12):2813-2820.
  15. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. Jama. 2007;298(3):309-316.
  16. Zulyniak MA, Roke K, Gerling C, Logan SL, Spriet LL, Mutch DM. Fish oil regulates blood fatty acid composition and oxylipin levels in healthy humans: A comparison of young and older men. Mol Nutr Food Res. 2016;60(3):631-641.
  17. Fabbrini E, Mohammed BS, Korenblat KM, et al. Effect of Fenofibrate and Niacin on Intrahepatic Triglyceride Content, Very Low-Density Lipoprotein Kinetics, and Insulin Action in Obese Subjects with Nonalcoholic Fatty Liver Disease. The Journal of Clinical Endocrinology & Metabolism.
  18. Strain WD, Paldanius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17(1):57.
  19. Diseases TNIoDaDaK. Insulin Resistance & Prediabetes. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance. Published 2018. Accessed October 28, 2019.
  20. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ (Clinical research ed). 2006;332(7533):73-78.
  21. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88(4):1167-1175.
  22. Kleefstra N, Bilo HJ, Bakker SJ, Houweling ST. [Chromium and insulin resistance]. Nederlands tijdschrift voor geneeskunde. 2004;148(5):217-220.
  23. Galloway SD, Craig TP, Cleland SJ. Effects of oral L-carnitine supplementation on insulin sensitivity indices in response to glucose feeding in lean and overweight/obese males. Amino Acids. 2011;41(2):507-515.
  24. Khan A, Safdar M, Ali Khan MM, Khattak KN, Anderson RA. Cinnamon Improves Glucose and Lipids of People With Type 2 Diabetes. Diabetes Care. 2003;26(12):3215.
  25. Tonetti MS, Van Dyke TE, Working group 1 of the joint EFPAAPw. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. Journal of clinical periodontology. 2013;40 Suppl 14:S24-29.
  26. D’Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. Journal of clinical periodontology. 2013;40 Suppl 14:S85-105.
  27. Rosenfeld ME. Inflammation and atherosclerosis: direct versus indirect mechanisms. Current opinion in pharmacology. 2013;13(2):154-160.
  28. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Current opinion in gastroenterology. 2015;31(1):69-75.
  29. Ma J, Li H. The Role of Gut Microbiota in Atherosclerosis and Hypertension. Frontiers in pharmacology. 2018;9:1082.
  30. Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB 30242 yoghurt formulation in hypercholesterolaemic adults. The British journal of nutrition. 2012;107(10):1505-1513.
  31. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized controlled trial. European journal of clinical nutrition. 2012;66(11):1234-1241.
  32. https://www.urmc.rochester.edu/encyclopedia/content.aspx?contenttypeid=85&contentid=P00402. Published 2019. Accessed.
  33. Wildman RP, Colvin AB, Powell LH, et al. Associations of endogenous sex hormones with the vasculature in menopausal women: the Study of Women’s Health Across the Nation (SWAN). Menopause (New York, NY). 2008;15(3):414-421.
  34. Publishing HH. Sex hormones and your hear. https://www.health.harvard.edu/heart-health/sex-hormones-and-your-heart. Published 2019. Accessed.
  35. Publishing HH. Testosterone — What It Does And Doesn’t Do. https://www.health.harvard.edu/drugs-and-medications/testosterone–what-it-does-and-doesnt-do. Published 2015. Accessed December 1, 2019.
  36. Goodale T, Sadhu A, Petak S, Robbins R. Testosterone and the Heart. Methodist DeBakey cardiovascular journal. 2017;13(2):68-72.
  37. Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies. J Sex Med. 2018;15(6):820-838.
  38. Cattabiani C, Basaria, S., Ceda, G.P. et al. . Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35.
  39. Tivesten A, Vandenput L, Carlzon D, et al. Dehydroepiandrosterone and its sulfate predict the 5-year risk of coronary heart disease events in elderly men. J Am Coll Cardiol. 2014;64(17):1801-1810.
  40. Budoff MJ, Ellenberg SS, Lewis CE, et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. Jama. 2017;317(7):708-716.
  41. Khosla S, Melton LJ, 3rd, Riggs BL. Estrogens and bone health in men. Calcified tissue international. 2001;69(4):189-192.
  42. Jankowska EA, Rozentryt P, Ponikowska B, et al. Circulating Estradiol and Mortality in Men With Systolic Chronic Heart Failure. JAMA. 2009;301(18):1892-1901.
  43. Ärnlöv J, Pencina MJ, Amin S, et al. Endogenous Sex Hormones and Cardiovascular Disease Incidence in Men. Annals of Internal Medicine. 2006;145(3):176-184.
  44. Campagnoli C, Clavel-Chapelon F, Kaaks R, Peris C, Berrino F. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer. J Steroid Biochem Mol Biol. 2005;96(2):95-108.
  45. Lobo RA. Hormone-replacement therapy: current thinking. Nature Reviews Endocrinology. 2017;13(4):220-231.
  46. Arnson Y, Rozanski A, Gransar H, et al. HORMONE REPLACEMENT THERAPY IS ASSOCIATED WITH LESS CORONARY ATHEROSCLEROSIS AND LOWER MORTALITY. Journal of the American College of Cardiology. 2017;69(11 Supplement):1408.
  47. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ : British Medical Journal. 2012;345:e6409.
  48. Zhao D, Guallar E, Ouyang P, et al. Endogenous Sex Hormones and Incident Cardiovascular Disease in Post-Menopausal Women. Journal of the American College of Cardiology. 2018;71(22):2555.
  49. Cannon RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clinical chemistry. 1998;44(8):1809.
  50. Naseem KM. The role of nitric oxide in cardiovascular diseases. Molecular aspects of medicine. 2005;26(1):33-65.
  51. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. Journal of atherosclerosis and thrombosis. 2005;12(2):111-119.
  52. von Haehling S, Anker SD, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart failure reviews. 2003;8(1):99-106.
  53. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep. 2006;8(2):100-106.
  54. Sun A, Chen H-M, Cheng S-J, et al. Significant association of deficiencies of hemoglobin, iron, vitamin B12, and folic acid and high homocysteine level with recurrent aphthous stomatitis. Journal of Oral Pathology & Medicine. 2015;44(4):300-305.
  55. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology. 2002;58(10):1471-1475.
  56. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Advances in nutrition (Bethesda, Md). 2012;3(1):1-7.
  57. Kassi E, Adamopoulos C, Basdra EK, Papavassiliou AG. Role of Vitamin D in Atherosclerosis. Circulation. 2013;128(23):2517-2531.
  58. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008;168(12):1340-1349.
  59. Health NIo. Vitamin K: Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/vitaminK-HealthProfessional/. Published 2019. Accessed Ocotber 24, 2019.
  60. Plank F, Beyer C, Friedrich G, et al. Influence of vitamin K antagonists and direct oral anticoagulation on coronary artery disease: A CTA analysis. Int J Cardiol. 2018;260:11-15.
  61. Shea MK, O’Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. The American Journal of Clinical Nutrition. 2009;89(6):1799-1807.
  62. Knapen MH, Braam LA, Drummen NE, Bekers O, Hoeks AP, Vermeer C. Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial. Thrombosis and haemostasis. 2015;113(5):1135-1144.
  63. Mansour AG, Hariri E, Daaboul Y, et al. Vitamin K2 supplementation and arterial stiffness among renal transplant recipients-a single-arm, single-center clinical trial. Journal of the American Society of Hypertension : JASH. 2017;11(9):589-597.
  64. Cerit L. Fibrinogen and Atherosclerosis. Arquivos brasileiros de cardiologia. 2017;108(2):189-190.
  65. Liu MY, Hu DY. [The predictive value of serum advanced fibrinogen and uric acid for acute coronary event risk]. Zhonghua yi xue za zhi. 2006;86(10):678-680.
  66. Høstmark AT, Bjerkedal T, Kierulf P, Flaten H, Ulshagen K. Fish oil and plasma fibrinogen. BMJ (Clinical research ed). 1988;297(6642):180-181
  67. Weng Y, Yao J, Sparks S, Wang KY. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. International journal of molecular sciences. 2017;18(3):523.
  68. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. 2003;107(3):398-404.
  69. Asher J, Houston M. Statins and C-reactive protein levels. Journal of clinical hypertension (Greenwich, Conn). 2007;9(8):622-628.
  70. Banerjee M, Tripathi LM, Srivastava VM, Puri A, Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacology and immunotoxicology. 2003;25(2):213-224.
  71. Ngondi JL, Etoundi BC, Nyangono CB, Mbofung CM, Oben JE. IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation. Lipids in health and disease. 2009;8:7-7.
  72. Biniaz V, Sadeghi Shermeh M, Ebadi A, Tayebi A, Einollahi B. Effect of Vitamin C Supplementation on C-reactive Protein Levels in Patients Undergoing Hemodialysis: A Randomized, Double Blind, Placebo-Controlled Study. Nephro-urology monthly. 2013;6(1):e13351-e13351.
  73. Tabrizi R, Vakili S, Akbari M, et al. The effects of curcumin-containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta-analysis of randomized controlled trials. Phytother Res. 2019;33(2):253-262.
  74. Bowden RG, Wilson RL, Deike E, Gentile M. Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease. Nutr Clin Pract. 2009;24(4):508-512.
  75. Reed GW, Leung K, Rossetti RG, Vanbuskirk S, Sharp JT, Zurier RB. Treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial. Evidence-based complementary and alternative medicine : eCAM. 2014;2014:857456-857456.
  76. Ma Y, Griffith JA, Chasan-Taber L, et al. Association between dietary fiber and serum C-reactive protein. The American journal of clinical nutrition. 2006;83(4):760-766.
  77. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99(24):15596-15601.
  78. Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. Journal of molecular medicine (Berlin, Germany). 2005;83(5):329-342.
  79. Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. 2019;51(2):165-176.
  80. Wu D, Sharan C, Yang H, et al. Apolipoprotein E-deficient lipoproteins induce foam cell formation by downregulation of lysosomal hydrolases in macrophages. Journal of lipid research. 2007;48(12):2571-2578.
  81. Mahley RW. Apolipoprotein E: from cardiovascular disease to neurodegenerative disorders. Journal of molecular medicine (Berlin, Germany). 2016;94(7):739-746.
  82. Bouchareychas L, Raffai RL. Apolipoprotein E and Atherosclerosis: From Lipoprotein Metabolism to MicroRNA Control of Inflammation. J Cardiovasc Dev Dis. 2018;5(2).
  83. Targońska-Stępniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators of inflammation. 2014;2014:793628-793628.
  84. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). 2004;109(6):726-732.
  85. Getz GS, Krishack PA, Reardon CA. Serum amyloid A and atherosclerosis. Curr Opin Lipidol. 2016;27(5):531-535.
  86. King VL, Thompson J, Tannock LR. Serum amyloid A in atherosclerosis. Current Opinion in Lipidology. 2011;22(4):302-307.
  87. Sack GH. Serum amyloid A – a review. Molecular Medicine. 2018;24(1):46.
  88. Aggarwal BB, Gupta SC, Sung B. Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers. Br J Pharmacol. 2013;169(8):1672-1692.
  89. Silva AM, Oliveira MI, Sette L, et al. Resveratrol as a natural anti-tumor necrosis factor-alpha molecule: implications to dendritic cells and their crosstalk with mesenchymal stromal cells. PLoS One. 2014;9(3):e91406.
  90. Jamaluddin MS, Weakley SM, Yao Q, Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 2012;165(3):622-632.
  91. Hyeong Kyu Park1 MKK, Hye Jeong Kim1, Rexford S. Ahima2. Linking resistin, inflammation, and cardiometabolic diseases FAU – Park, Hyeong Kyu FAU – Kwak, Mi Kyung FAU – Kim, Hye Jeong FAU – Ahima, Rexford S. The Korean journal of internal medicine. 2017;32(2):239-247.
  92. Chu S, Ding W, Li K, Pang Y, Tang C. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circulation journal : official journal of the Japanese Circulation Society. 2008;72(8):1249-1253.
  93. Bo S, Ciccone G, Durazzo M, et al. Efficacy of antioxidant treatment in reducing resistin serum levels: a randomized study. PLoS Clin Trials. 2007;2(5):e17-e17.
  94. Dehghani S, Alipoor E, Salimzadeh A, et al. The effect of a garlic supplement on the pro-inflammatory adipocytokines, resistin and tumor necrosis factor-alpha, and on pain severity, in overweight or obese women with knee osteoarthritis. 2018;48:70-75.
  95. Morioka T, Emoto M, Yamazaki Y, et al. Leptin is associated with vascular endothelial function in overweight patients with type 2 diabetes. Cardiovascular diabetology. 2014;13:10-10.
  96. Askari H, Tykodi G, Liu J, Dagogo-Jack S. Fasting plasma leptin level is a surrogate measure of insulin sensitivity. The Journal of clinical endocrinology and metabolism. 2010;95(8):3836-3843.
  97. Gijon-Conde T, Graciani A, Guallar-Castillon P, Aguilera MT, Rodriguez-Artalejo F, Banegas JR. Leptin Reference Values and Cutoffs for Identifying Cardiometabolic Abnormalities in the Spanish Population. Rev Esp Cardiol (Engl Ed). 2015;68(8):672-679.
  98. Ahima RS. Revisiting leptin’s role in obesity and weight loss. The Journal of clinical investigation. 2008;118(7):2380-2383.
  99. Rubenfire M, American College of Cardiology. Lipoprotein(a): Diagnosis, Prognosis, Emerging Therapies. https://www.acc.org/latest-in-cardiology/ten-points-to-remember/2017/02/07/14/21/a-test-in-context-lipoproteina-diagnosis. Published 2017. Accessed Jun. 27, 2019.
  100. Menzel D, Haller H, Wilhelm M, Robenek H. l-Arginine and B vitamins improve endothelial function in subjects with mild to moderate blood pressure elevation. European journal of nutrition. 2018;57(2):557-568.
Scroll to Top

THE TROUBLED TUMMY GUIDE

The 6 Keys to Reversing Pain, Embarrassment, and Discomfort.

Anti-Inflammatory & Digestion Enhancing Recipes.

Enjoy a Healthy Happy Tummy.